Making it in Manufacturing

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

What does it take to build a CDMO designed around speed, integration, and true scientific collaboration?

This week on Making It In Manufacturing, Harry Sloan sat down with LakshmiDevi Ethirajan, Co-Founder & CEO of SmaBioLabs, with 25+ years of experience spanning big pharma, small pharma, and CDMO leadership roles across drug development and manufacturing.

In this episode, LakshmiDevi Ethirajan covers:

• How a background in pharmacy and pharmaceutical development led to the creation of SmaBioLabs and the vision behind building a fully integrated CDMO

• Why bringing discovery, formulation development, and analytical services together under one roof reduces risk and improves program execution

• The importance of speed and flexibility in pharmaceutical development, including why projects at SmaBioLabs begin within two weeks of contract signing

• How technical integration between discovery scientists and formulation teams supports complex molecules and improves development outcomes

• The long-term vision for SmaBioLabs, including commercial manufacturing expansion and becoming a complete end-to-end partner for sponsors

If you are involved in pharmaceutical manufacturing, biotech growth, CDMO strategy, or drug development leadership, this conversation offers a practical perspective on building scalable scientific partnerships in a rapidly evolving industry.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

LakshmiDevi Ethirajan

Co-Founder & CEO of SmaBioLabs

LinkedIn: https://www.linkedin.com/in/lakshmidevi-ethirajan/

Harry Sloan

BD CDMO Lead at ARTO

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction

00:14 LakshmiDevi Ethirajan’s journey into pharmaceuticals

01:07 Why sponsor and CDMO alignment matters

02:27 Building an end-to-end CDMO model

03:58 Speed and flexibility in drug development

05:00 Supporting complex molecules through integration

06:46 The meaning behind the SmaBio Labs name

07:56 Growth plans and commercial manufacturing ambitions

08:51 Standing out in the competitive CDMO market

10:17 The North Carolina biotech ecosystem

12:37 Leadership, culture, and patient impact

13:53 Closing remarks

#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #DrugDevelopment #Biotech #LifeSciences #ManufacturingLeadership #PharmaIndustry #Biotechnology #DrugDiscovery #AnalyticalServices #FormulationDevelopment

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

How do leading CDMOs move beyond manufacturing to become true development partners? In this episode, Jeffrey Speicher shares how integrated development, technical problem solving and long-term partnerships are shaping growth in outsourced pharma manufacturing.

This week on Making It In Manufacturing, Harry Sloan sat down with Jeffrey Speicher, General Manager Commercial of PLD Pharma, with over 30 years of experience spanning engineering, commercial leadership, contract manufacturing, OTC product development and strategic growth across the pharmaceutical and consumer healthcare sectors.

In this episode, Jeffrey Speicher covers:

- How PLDevelopments evolved from a private label manufacturer into a full CDMO model focused on end-to-end support for customers

- Why in-house development and commercialisation capabilities help accelerate speed to market and reduce manufacturing risk for pharmaceutical products

- The importance of designing formulations around commercial manufacturing equipment from the very beginning of the R&D process

- How product diversification across liquids, tablets, electrolytes, and gummies creates broader manufacturing capabilities within the CDMO market

- Why partnership-led relationships matter for pharmaceutical brands looking for quality, consistency, and long-term manufacturing support in the US market

For anyone operating across CDMO strategy, OTC innovation or outsourced development, this is a thoughtful conversation on what partnership-led manufacturing really looks like. Be sure to check out the full episode for a deeper discussion on leadership, commercial growth and differentiated execution in pharma services.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Jeffrey Speicher

General Manager Commercial at PLD Pharma

LinkedIn: https://www.linkedin.com/in/jeffrey-speicher-826746/

Harry Sloan

CDMO BD Lead at ARTO

LinkedIn: https://www.linkedin.com/in/harry-sloan/

Timestamps:

00:00 Introduction

00:21 Jeffrey Speicher introduction and overview of PL Developments

00:45 The origins of PL Developments and private label manufacturing

01:07 Transitioning into a CDMO-focused business model

01:25 What differentiates PL Developments from traditional CDMOs

01:44 The advantages of broad formulation and manufacturing capabilities

02:26 Why upstream development support improves project success

03:05 Connecting R&D with commercial manufacturing equipment

03:37 Speed to market and reducing commercialisation risk

03:55 Competing through partnership and customer focus

04:29 Balancing speed, efficiency, and scalability in manufacturing

05:09 Developing OTC gummies and expanding manufacturing capabilities

05:28 Designing products around plant strengths

05:40 Eliminating risk during commercial transfer

05:44 Closing remarks

#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #OTCManufacturing #DrugDevelopment #ContractManufacturing #LifeSciences

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

The CDMO landscape is crowded, fragmented, and increasingly complex. What does it take to stand out and lead in such a competitive space?

This week on Making It In Manufacturing, Harry Sloan sat down with Tom Sellig, CEO of Adare Pharma Solutions with a long-standing career spanning commercial leadership, pharma services, and executive roles across global organisations including, Procter and Gamble, Covance, Patheon, LabConnect, and Thermo Fisher Scientific.

In this episode, Tom Sellig covers:

- How Adare Pharma Solutions positions itself as a technology-driven oral solid dose CDMO with global capabilities across North America and Europe

- Why having both US and European manufacturing capabilities is critical for business continuity, regulatory navigation, and client needs in today’s geopolitical environment

- The key differentiators behind Adare’s success, including technological breadth, flexibility as a mid-sized CDMO, and the ability to support both large-scale and highly specialised projects

- Building a deeply embedded client-centric culture, including company-wide alignment and continuous customer feedback integration

For leaders navigating the CDMO and broader Life Sciences manufacturing space, this episode offers a grounded perspective on strategy, growth, and execution. Watch the full conversation for a clear view on what sustainable leadership in this sector really looks like.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Tom Sellig

CEO at Adare Pharma Services

LinkedIn: https://www.linkedin.com/in/tomsellig/

Harry Sloan

BD CDMO Lead at ARTO

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction

00:20 Overview of Adare Pharma Solutions

01:05 Importance of global footprint in CDMO services

01:45 Key differentiators in a competitive CDMO market

02:43 Client-centric culture and organisational alignment

03:40 Career journey and leadership development

04:25 Lessons from scaling and acquisitions at Patheon

05:05 The Adare framework and company values

05:57 Future outlook for Adare and the CDMO landscape

07:00 Closing remarks

#MakingItInManufacturing #ARTOTalent #CDMO #LifeSciences #PharmaManufacturing #Biopharma #Leadership

Hosted on Acast. See acast.com/privacy for more information.

What does it take to scale complex biologics manufacturing while keeping speed, quality, and communication aligned? In this episode, Ian Glassford explains how integrated CDMO partnerships are helping biotech companies accelerate ADC and bioconjugate programs from discovery through to commercial manufacturing.

This week on Making It In Manufacturing, Harry Sloan sat down with Ian Glassford, VP at Abzena, with more than a decade of experience spanning medicinal chemistry, synthetic chemistry, bioconjugation, biologics manufacturing, and CDMO leadership roles across GSK and Abzena.

In this episode, Ian Glassford covers:

• How Abzena approaches integrated ADC and bioconjugate manufacturing across discovery, development, and GMP production (00:00)

• Why communication and true partnership models are becoming critical for CDMOs supporting fast-moving biotech programs (02:55)

• The balance between speed to clinic, process standardisation, and maintaining manufacturing quality in complex biologics (03:37)

• Ian’s transition from medicinal chemistry at @GSK into leadership within the bioconjugation and ADC space at Abzena (08:11)

• Where the future of ADCs, AOCs, radionuclide conjugates, and commercial manufacturing is heading over the next five years (10:25)

For anyone working across biologics manufacturing, ADC development, CDMO partnerships, or complex therapeutics, this conversation offers a practical look at how experienced operators are adapting to increasingly demanding timelines and evolving modalities across the biotech industry.

Follow ARTO:

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Ian Glassford:

LinkedIn: https://www.linkedin.com/in/ian-glassford-phd-mba-28270529/

Harry Sloan:

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/?skipRedirect=true

Timestamps:

00:00 Introduction and live recording from DCAT Week in New York

00:39 Ian Glassford explains Abzena’s role in the ADC and bioconjugate CDMO market

01:25 The biggest operational challenges in ADC and AOC manufacturing

02:43 What biotech clients are really looking for beyond technical expertise

03:37 Managing the balance between speed, quality, and execution

04:53 How integrated CDMO and CRO models improve timelines and supply chain control

06:43 The importance of communication and partnership in complex programs

08:11 Ian’s career journey from medicinal chemistry into bio conjugates

10:00 Transitioning from hands-on science into site leadership

10:25 Where Abzena and the wider ADC market are heading in the next five years

11:51 Adapting CDMO models to support evolving biologics modalities

12:29 Closing thoughts

#MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #ADC #DrugDevelopment #Manufacturing #Pharmaceuticals #Bioconjugates

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

How do leading CDMOs move beyond scale to become true strategic partners?

This week on Making It In Manufacturing, Harry Sloan sat down with John Gagliardi, Sales Director, Key Account Management at Samsung Biologics, with 25+ years of experience spanning operations, supply chain, procurement, sourcing and commercial leadership across biopharma, including previous experience at GSK and leadership in CDMO partnerships.

In this episode, John Gagliardi covers:

- How Samsung Biologics has evolved as a pure-play CDMO, including US expansion and the value of integrated support from clinical development through commercial supply.

- Why long-term partnerships in biomanufacturing depend on value creation beyond capacity, from lifecycle management to flexible supply chain strategies.

- What credible ADC capability really looks like, including integrated manufacturing, simplified supply chains and how co-located operations can accelerate speed to market.

- The strategic importance of the Lilly Gateway Labs collaboration with Eli Lilly, and how incubating early-stage biotech can strengthen the future innovation ecosystem.

- Where growth is heading next for Samsung Biologics, from Bio Campus expansion and emerging modalities to scaling quality while maintaining operational agility.

If you are interested in where biomanufacturing partnerships are heading, and how leading CDMOs are thinking beyond capacity alone, this conversation offers practical insight worth your time.

Watch the full episode to hear how John approaches growth, innovation and patient impact through a commercial and operational lens.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

John Gagliardi

Sales Director at Samsung Biologics

LinkedIn: https://www.linkedin.com/in/john-gagliardi-7a8a252/

Harry Sloan

CDMO BD Lead at ARTO

LinkedIn: linkedin.com/in/harry-sloan-605620154/?lipi=urn%3Ali%3Apage%3Ad_flagship3_profile_view_base%3B7ieBaX%2FATH6lSPMIPdsI8w%3D%3D

Timestamps:

00:00 Introduction from New York and conference spotlight

00:42 Samsung Biologics as a pure-play CDMO

02:10 Building strategic customer partnerships

03:45 Differentiation beyond standard CDMO models

05:01 Building credibility in ADC manufacturing

07:53 Technical collaboration and winning partnerships

09:07 Lilly Gateway Labs collaboration

11:40 Growth trajectory and future modalities

13:19 Scaling while maintaining quality

15:00 Patient impact and personal motivation

16:35 Closing remarks

#MakingItInManufacturing #ARTOTalent #Biomanufacturing #CDMO #Biopharma #SupplyChain #ADC #PharmaceuticalManufacturing #BiotechLeadership

Hosted on Acast. See acast.com/privacy for more information.

What does it really take to build credibility as a new CDMO in a highly competitive biologics market, while staying grounded in patient impact?

This week on Making It In Manufacturing, Harry Sloan sat down with Joon Chang, Chief Business Officer at Lotte Biologics, with years of experience spanning Pharma, CDMO, project management, and business development roles across global organisations.

In this episode, Joon Chang covers:

• (02:17) Building credibility as a new CDMO and overcoming the challenge of limited track record while leveraging experienced talent from legacy manufacturing sites

• (03:05) Why people and expertise matter more than company age when delivering successful tech transfer, development, and manufacturing outcomes

• (04:17) The importance of tailoring partnerships to individual client needs and building long-term relationships across Pharma and biotech organisations

• (07:00) Career journey from bench scientist to commercial leadership, and how experience across Pharma and CDMO environments shapes client-centric thinking

• (10:10) Creating a patient-centric culture in manufacturing and commercial teams, and why connecting daily operations to patient impact strengthens partnerships

If you are interested in how emerging CDMOs can differentiate themselves through culture, capability, and client alignment, this episode offers a grounded and practical perspective worth your time.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Joon Chang

LinkedIn: https://www.linkedin.com/in/joon-chang-a337895/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction at the DCAT Conference

00:33 Overview of Lotte Biologics and market positioning

01:20 Capabilities in biologics manufacturing and conjugation

02:01 Challenges of entering the CDMO market as a new player

03:05 Importance of talent and retained expertise from legacy sites

03:52 Building relationships with Pharma and biotech clients

04:24 Dual hub model across the US and South Korea

05:01 Manufacturing scale advantages and commercial readiness

06:19 Speed, cost efficiency, and internal tech transfer benefits

07:00 Career journey from Pharma to CDMO leadership

08:04 Understanding client mindset from both Pharma and CDMO perspectives

08:54 Project management experience and client relationship ownership

09:43 Leadership philosophy and full lifecycle thinking

10:10 Building an ideal organisational culture

10:40 Patient-centric approach and ultra-rare disease considerations

11:43 Connecting operations to patient impact

12:34 Applying culture to commercial and sales teams

13:21 Business development mission and value creation

13:40 Leadership approach and empowering teams

15:00 Vision for disrupting the CDMO industry

16:21 Growth, partnerships, and expanding patient reach

17:01 Personal motivation and purpose behind the work

18:00 Team culture and collaboration

#MakingItInManufacturing #ARTOTalent #Biologics #CDMO #Pharma #Biotech #Manufacturing

Hosted on Acast. See acast.com/privacy for more information.

From hands-on pharmacology research to leading strategic projects in advanced manufacturing, this episode explores what it really takes to evolve, adapt, and lead across decades of change in life sciences.

This week on Making It In Manufacturing, Harry Sloan sat down with Alison Clayton, Strategic Projects Director at Symbiosis, with over 40 years of experience spanning pharmacology research, pre-clinical and clinical development, and pharmaceutical manufacturing.

In this episode, Alison Clayton covers:

(00:00) Transitioning from academia into industry and navigating major company acquisitions early in a career

(01:40) Moving beyond the lab into strategic, customer-facing roles and discovering a passion for leadership

(03:35) Adapting to constant organisational change while maintaining a patient-first mindset

(07:26) The risks of scaling too quickly in CDMOs and the importance of realistic capacity and strong partnerships

(10:02) Maintaining quality and regulatory standards while growing in a highly competitive pharmaceutical landscape

This conversation offers a grounded perspective on long-term career development, leadership in complex environments, and the evolving demands of pharmaceutical manufacturing. If you are building a career in life sciences or scaling within a CDMO environment, this episode provides practical insights worth applying.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Alison Clayton

LinkedIn: https://www.linkedin.com/in/alison-clayton-78816711/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction to the episode

00:14 Alison Clayton introduction and career reflection

00:53 Transition from academia to industry

01:15 Experience at Syntex Pharmaceuticals, Roche, and Quintiles

01:40 Moving into strategic and customer-facing roles

02:24 Leadership style shaped by scientific background

02:50 End-to-end experience across drug development

03:13 Navigating challenges and career-defining moments

03:35 Adapting through multiple company transitions

04:24 Balancing commercial goals with patient outcomes

04:56 Experiences in a male-dominated industry

05:51 Advice for women in life sciences leadership

06:09 Career development without a fixed plan

07:00 Balancing career and family life

07:26 Scaling challenges in CDMOs

08:30 Risks of overpromising and underdelivering

09:28 Importance of supply chain and transparency

10:02 Maintaining quality and regulatory compliance

10:27 Overview of Symbiosis

10:57 Market demand for sterile manufacturing

11:20 Scottish identity and company culture

11:39 Differentiation in the CDMO market

12:31 Importance of flexibility and partnerships

13:21 Building long-term client relationships

13:41 Future outlook for Symbiosis

14:05 Evolution of biologics and impact on patients

14:32 Career reflection and delivering medicines to patients

15:17 What excites Alison about the future

#MakingItInManufacturing #ARTOTalent #PharmaceuticalManufacturing #LifeSciences #CDMO #Biologics #DrugDevelopment

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

The CDMO model is evolving fast, but what actually separates the leaders from the rest in today’s market?

This week on Making It In Manufacturing, Harry Sloan sat down with Thierry Van Nieuwenhove, CEO of Quotient Sciences, with 25+ years of experience spanning business development, engineering, global manufacturing leadership, and executive roles.

In this episode, Thierry covers:

• The evolution of the CDMO landscape over 25 years, from API-focused events to a global, multi-disciplinary pharma ecosystem

• How Quotient Sciences built a unique translational pharmaceutics platform to combine clinical studies with drug manufacturing, accelerating development timelines by up to 12 months

• A career journey from chemical engineering into global business development and leadership, including building manufacturing capabilities in India and working across Europe and the US

• Why speed, efficiency, and proof of concept are critical in today’s funding-constrained biotech environment

• The growing impact of AI, global innovation shifts including China, and how CDMOs must adapt to remain competitive and support emerging biotech pipelines

If you are looking to understand where the CDMO space is heading, and what it takes to lead in a rapidly evolving pharmaceutical market, this episode offers a clear and practical perspective. Be sure to watch the full conversation.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@life_sciences

Thierry Van Nieuwenhove

CEO at Quotient Sciences

LinkedIn: https://www.linkedin.com/in/thierryvan/

Harry Sloan

BD CDMO Lead

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction to Making It In Manufacturing at DCAT

00:20 Meet Thierry Van Nieuwenhove, CEO of Quotient Sciences

01:40 Overview of Quotient Sciences and translational pharmaceutics

03:10 Competitive advantage in the CDMO market

04:23 Career journey from engineering to CEO

07:00 Leadership development across global roles

08:18 Operating across international markets and cultures

09:17 Translating early-stage assets into clinical success

12:00 Industry challenges including funding constraints

14:25 AI, partnerships, and innovation in formulation

16:01 Data science and accelerating development timelines

17:32 Global trends including China’s role in innovation

19:56 Strategic adaptation to industry shifts

21:34 Demand for integrated CDMO models

22:55 Customer expectations: speed, excellence, and innovation

25:28 The importance of trust and long-term partnerships

#MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #Biotech #DrugDevelopment #LifeSciences

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

What does it really take to move from science into CEO leadership while delivering real impact for patients?

This week on Making It In Manufacturing, Harry Sloan sat down with Dr Adriana Kiedzierska-Mencfeld, CEO of Rezon Bio, with 20 years of experience spanning biotech, biologics manufacturing, and leadership across industry and scientific roles.

In this episode, Dr Adriana Kiedzierska-Mencfeld covers:

- Transitioning from academia to industry and the drive to turn science into real patient value

- Key leadership moments including entering new technology areas and managing high-pressure decision making

- Leading through COVID, maintaining operations, and ensuring both product delivery and team safety

- Transforming into a CDMO model and leading organisational change with clarity and purpose

- Competing in a crowded CDMO market through cost discipline, quality standards, and operational efficiency

If you are working in biotech, manufacturing, or scaling scientific innovation into real-world impact, this conversation offers a clear and grounded perspective on leadership, decision making, and building high-performing teams under pressure.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Dr Adriana Kiedzierska-Mencfeld

LinkedIn: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction

00:33 Moving beyond science into leadership

02:06 Career-defining moments and leadership growth

04:56 Leading through COVID and regulatory pressure

06:01 FDA inspection and managing high-stakes environments

07:13 Transition to CDMO and company transformation

09:20 Launch of Resins Bio and stepping into CEO role

11:39 Building trust and delivering for clients

12:29 Cost competitiveness and market positioning

14:20 Speed, quality, and CDMO differentiation

15:22 Market trends and opportunities in biologics

17:33 CDMO positioning and capabilities

18:09 Balancing existing clients and new business

20:08 Personal career journey and challenges

21:44 Advice for women in biotech leadership

22:46 Future of biologics manufacturing

24:33 Motivation and leadership purpose

#MakingItInManufacturing #ARTOTalent #Biotech #CDMO #Biologics #LifeSciences #ManufacturingLeadership

Hosted on Acast. See acast.com/privacy for more information.

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes.

What does it take to scale pharmaceutical packaging operations globally while maintaining flexibility, quality, and speed to market? In this episode, we explore how strategic packaging partnerships directly impact patient access and commercial success.

This week on Making It In Manufacturing, Harry Sloan sat down with Peter Belden, CCO of Tjoapack, with over 25 years of experience spanning outsourced pharmaceutical services across small, mid-sized, and large organisations, primarily within packaging and global supply chain operations.

In this episode, Peter Belden covers:

00:00 How pharmaceutical packaging plays a critical role beyond the final step, directly influencing timelines and global market access

01:25 The growing need for late-stage customisation and flexible packaging to meet changing patient demand across multiple markets

02:21 Why successful CDMO partnerships start with deep client understanding, including patient population, dosing, and supply chain needs

03:43 Balancing speed to market with quality through strong planning, collaboration, and supply chain alignment

04:43 Strategic expansion in the US, including facility growth and new packaging lines to support long-term demand

This conversation offers a practical look at how packaging strategy, operational discipline, and global experience come together to support pharmaceutical innovation at scale. If you are involved in manufacturing, supply chain, or CDMO partnerships, this episode provides valuable perspective grounded in real industry execution.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com/

Youtube: https://www.youtube.com/@artotalent

Peter Belden

LinkedIn: https://www.linkedin.com/in/petersbelden/

Harry Sloan

LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/

Timestamps:

00:00 Introduction

00:15 Overview of the company and CDMO positioning

01:04 Evolution of pharmaceutical packaging and flexibility

01:48 Late-stage customisation and supply chain adaptability

02:21 Building strong client partnerships in packaging

02:56 Scoping projects and delivering tailored solutions

03:21 Industry change and demand for speed to market

03:43 Balancing quality with responsiveness

04:20 Supply chain collaboration and planning cadence

04:34 US expansion and growth strategy

05:06 Facility expansion and new packaging lines

05:31 Managing growth and operational challenges

06:07 Long-term vision and scaling capabilities

06:50 Career journey into leadership

07:31 International experience and UK market integration

08:39 Adapting to global markets and client needs

09:03 Delivering across 40+ countries

10:05 Motivation and impact on patient access

10:22 Closing remarks

#MakingItInManufacturing #ARTOTalent #PharmaManufacturing #CDMO #SupplyChain #Biopharma

Hosted on Acast. See acast.com/privacy for more information.